Bacteriophage gene 3 protein compositions and use as amyloid binding agents
AssigneeProclara Biosciences, Inc.
InventorsRajaraman Krishnan, Richard Fisher
Life of this patent
Estimating the term…
Abstract
The invention relates to agents and to pharmaceutical compositions for reducing the formation of amyloid and/or for promoting the disaggregation of amyloid proteins. The compositions may also be used to detect amyloid.
Claims27
A method of treating a subject for a disease or disorder associated with misfolded and/or aggregated amyloid beta, tau, α-synuclein, and/or prion protein, comprising administering to the subject an amyloid-binding polypeptide, wherein the polypeptide comprises at least one of:
- (a) a wild-type M13 g3p (SEQ ID NO:1),
- (b) an amyloid-binding fragment of wild-type M13 g3p, or
- (c) a mutant of (a) or (b) that is at least 95% identical to SEQ ID NO:1 or an amyloid-binding fragment of SEQ ID NO:1;
- and wherein the subject is not administered a filamentous bacteriophage.
A method of treating a subject for a disease or disorder associated with misfolded and/or aggregated amyloid beta, tau, α-synuclein, and/or prion protein, comprising administering to the subject a fusion protein, wherein the fusion protein comprises an amyloid-binding polypeptide and an immunoglobulin constant region, wherein the amyloid-binding polypeptide comprises at least one of:
- (a) a wild-type M13 g3p (SEQ ID NO:
- 1),
- (b) an amyloid-binding fragment of wild-type M13 g3p, or
- (c) a mutant of (a) or (b) that is at least 95% identical to SEQ ID NO:
- 1 or an amyloid-binding fragment of SEQ ID NO:
- 1.
Dependencies are inferred from the claim text.